EXCO Resources Inc. Downgraded To 'B' On Revised Price Deck Assumptions; Outlook Negative May 12

  • ID: 2127744
  • May 2012
  • Standard & Poors
1 of 3

On April 18, 2012, Standard & Poor's Ratings Services lowered its natural gas price assumptions for 2012, 2013, and 2014. As a result, we expect U.S. exploration and production (E&P) company Exco Resources Inc. to post weaker profitability and credit measures. We are lowering our long-term corporate credit rating on Exco to 'B' from 'B+'. We are also lowering our issue rating on Exco's senior unsecured debt to 'CCC+' from 'B-'. The negative outlook reflects our expectation that Exco's credit measures will deteriorate and remain weak for the rating category over the next 12 months. DALLAS (Standard & Poor's) May 9, 2012--Standard & Poor's Ratings Services said today that it lowered its corporate credit rating on Dallas-based Exco Resources Inc....

Companies mentioned in this report are:
- EXCO Resources Inc.

Action: Downgraded
Action: Outlook: Negative

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- EXCO Resources Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.